Askgene Pharma, Inc.
Clinical trials sponsored by Askgene Pharma, Inc., explained in plain language.
-
New eye drug shows promise in early trial for blinding disease
Disease control OngoingThis early-stage study tests an experimental drug called ASKG712, given as an eye injection, for people with wet age-related macular degeneration (a leading cause of vision loss). The main goal is to check safety and how the body handles the drug, with 56 participants receiving d…
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 17, 2026 02:43 UTC
-
New eye drug shows promise for Diabetes-Related vision loss
Disease control OngoingThis early-stage trial tests an experimental drug called ASKG712, given as an eye injection, for people with diabetic macular edema (DME) — a condition that causes vision loss in people with diabetes. The study involves 26 participants and focuses on safety and how the drug moves…
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 17, 2026 02:41 UTC
-
New drug combo shows promise in stomach cancer battle
Disease control OngoingThis study tests whether adding the drug ASKB589 to standard chemotherapy and immunotherapy can help people with advanced stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 780 adults whose tumors have a specific marker (CLDN18.2) w…
Phase: PHASE3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for advanced stomach cancer: triple therapy shows promise
Disease control OngoingThis study tests a new drug, ASKB589, combined with chemotherapy (CAPOX) and an immunotherapy (PD-1 inhibitor) in 62 people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps control…
Phase: PHASE1, PHASE2 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC